ssgj-705
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT05145179)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07022002 | Phase 2 | Jul 30, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT06390774 | Phase 1 | May 30, 2024 | Sunshine Lake Pharma Co., Ltd. |
| NCT05145179 | Phase 1 | Dec 1, 2021 | Jilin Provincial Tumor Hospital, People's Liberation Army of China, Sunshine Lake Pharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
| Jilin Provincial Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1